Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Int J Psychophysiol ; 62(2): 243-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16814888

ABSTRACT

We have previously reported that subjects with posttraumatic stress disorder (PTSD) differ from trauma controls in their ability to produce and withhold responses in the Stop-Signal Task depending on the motivational context as determined by financial reward. This experiment measured skin conductance and heart rate to assess autonomic changes accompanying these different patterns of behavior. Fowles hypothesized that heart rate would increase with behavioral activation and that increases in skin conductance would accompany behavioral inhibition. Both PTSD and comparison groups showed the expected behavioral changes in response to rewards, but they differed in their physiological responses. The subjects in the traumatized comparison group showed changes in skin conductance and heart rate consistent with Fowles' hypothesis and the observed changes in behavioral inhibition and activation. However, PTSD subjects showed no significant change in either physiological measure. These results demonstrate a dissociation between autonomic reactivity and motivated behavior in PTSD that may represent one aspect of emotional numbing.


Subject(s)
Dissociative Disorders/physiopathology , Dissociative Disorders/psychology , Stress Disorders, Post-Traumatic/physiopathology , Stress Disorders, Post-Traumatic/psychology , Adult , Anxiety/physiopathology , Anxiety/psychology , Depression/physiopathology , Depression/psychology , Emotions/physiology , Female , Galvanic Skin Response/physiology , Heart Rate/physiology , Humans , Male , Middle Aged , Motivation , Psychomotor Performance/physiology , Reward
2.
Psychopharmacology (Berl) ; 161(1): 86-94, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11967635

ABSTRACT

RATIONALE: Benzodiazepines are among the most frequently prescribed drugs and are usually taken by mouth. However, there have been few studies of oral self-administration of these drugs, and the results of IV self-administration studies indicate that benzodiazepines are modest reinforcers. OBJECTIVES: To determine if orally delivered alprazolam, diazepam, and triazolam could serve as reinforcers for rhesus monkeys, and to determine some of the conditions under which benzodiazepine reinforced behavior occurs. METHODS: Diazepam or midazolam was initially established as a reinforcer by a fading procedure whereby increasing concentrations were added to a 1 or 2% ethanol solution, and subsequently the ethanol concentration was decreased in steps to zero. Diazepam- and midazolam-reinforced responding persisted in the absence of ethanol. Triazolam and alprazolam served as reinforcers when substituted for diazepam or midazolam. RESULTS: Alprazolam, diazepam, and triazolam served as effective reinforcers across a wide range of concentrations and under fixed-ratio sizes of 16 and 32. Rates of responding were usually far higher than that for the concurrently available vehicle, water. Drug intake (mg drug/kg body weight) generally increased with increases in drug concentration. When large drug amounts were consumed, signs of intoxication were observed. CONCLUSIONS: In contrast to reports of low response rates and weakly maintained behavior, the present results show that the three benzodiazepines can serve as effective reinforcers.


Subject(s)
Alprazolam/pharmacology , Anti-Anxiety Agents/pharmacology , Diazepam/pharmacology , Reinforcement, Psychology , Triazolam/pharmacology , Administration, Oral , Animals , Macaca mulatta , Male , Self Administration
3.
Alcohol Clin Exp Res ; 25(6): 847-9, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11410720

ABSTRACT

BACKGROUND: Recently, we showed by using self-report that combining ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day) was effective at reducing drinking and increasing abstinence among early-onset alcoholics (EOAs), who are characterized by a range of antisocial behaviors and high biological and familial disease predisposition. Here, we investigated whether the self-reported differences in drinking would be corroborated by measurements of serum carbohydrate-deficient transferrin (CDT) level, a sensitive, reliable, and well-validated marker of transient alcohol consumption. METHOD: An 8-week double-blind clinical trial was performed in which 20 EOAs were randomized to receive ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day) or placebo as an adjunct to weekly standardized cognitive behavioral therapy. Serum CDT was assessed at weeks 0 (baseline), 4, and 8. RESULTS: Log serum CDT was significantly lower in the ondansetron and naltrexone group (group mean, 1.44 +/- 0.076) compared with the placebo group (group mean, 1.82 +/- 0.113), as evidenced by a main effect of group [F(1,15) = 7.2, p = 0.017; effect size = 0.32], visit [F(1,16) = 11.2, p = 0.004; effect size = 0.41], and an interaction between group and visit [F(1,16) = 27.54, p < 0.001; effect size = 0.63]. CONCLUSIONS: The combination of ondansetron plus naltrexone was superior to placebo at reducing serum CDT. This corroborated our self-reported drinking data and demonstrated that the medication combination is an effective treatment for EOAs.


Subject(s)
Alcohol Drinking/blood , Alcoholism/drug therapy , Biomarkers/blood , Naltrexone/administration & dosage , Ondansetron/administration & dosage , Transferrin/analysis , Adult , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Male , Naltrexone/therapeutic use , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/therapeutic use , Ondansetron/therapeutic use , Placebos , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/therapeutic use , Transferrin/analogs & derivatives
4.
JAMA ; 284(8): 963-71, 2000.
Article in English | MEDLINE | ID: mdl-10944641

ABSTRACT

CONTEXT: Early-onset alcoholism differs from late-onset alcoholism by its association with greater serotonergic abnormality and antisocial behaviors. Thus, individuals with early-onset alcoholism may be responsive to treatment with a selective serotonergic agent. OBJECTIVE: To test the hypothesis that drinking outcomes associated with early vs late-onset alcoholism are differentially improved by the selective 5-HT(3) (serotonin) antagonist ondansetron. DESIGN: Double-blind, randomized, placebo-controlled clinical trial. SETTINGS: University of Texas Health Science Center in Houston (April 1995-June 1998) and University of Texas Health Science Center in San Antonio (July 1998-December 1999). PARTICIPANTS: A total of 321 patients with diagnosed alcoholism (mean age, 40.6 years; 70.5% male; 78.6% white) were enrolled, 271 of whom proceeded to randomization. INTERVENTIONS: After 1 lead-in week of single-blind placebo, patients were randomly assigned to receive 11 weeks of treatment with ondansetron, 1 microg/kg (n = 67), 4 microg/kg (n = 77), or 16 microg/kg (n = 71) twice per day; or identical placebo (n = 56). All patients also participated in weekly standardized group cognitive behavioral therapy. MAIN OUTCOME MEASURES: Self-reported alcohol consumption (drinks per day, drinks per drinking day, percentage of days abstinent, and total days abstinent per study week); and plasma carbohydrate deficient transferrin (CDT) level, an objective and sensitive marker of transient alcohol consumption. RESULTS: Patients with early-onset alcoholism who received ondansetron (1, 4, and 16 microg/kg twice per day) compared with those who were administered placebo, had fewer drinks per day (1.89, 1.56, and 1.87 vs 3.30; P =.03, P =.01, and P =.02, respectively) and drinks per drinking day (4.75, 4.28, and 5.18 vs 6.90; P =.03, P =.004, and P =.03, respectively). Ondansetron, 4 microg/kg twice per day, was superior to placebo in increasing percentage of days abstinent (70.10 vs 50.20; P =.02) and total days abstinent per study week (6.74 vs 5.92; P =.03). Among patients with early-onset alcoholism, there was a significant difference in the mean log CDT ratio between those who received ondansetron (1 and 4 microg/kg twice per day) compared with those who received the placebo (-0.17 and -0.19 vs 0.12; P =.03 and P =.01, respectively). CONCLUSION: Our results suggest that ondansetron (particularly the 4 microg/kg twice per day dosage) is an effective treatment for patients with early-onset alcoholism, presumably by ameliorating an underlying serotonergic abnormality. JAMA. 2000;284:963-971


Subject(s)
Alcoholism/prevention & control , Ondansetron/therapeutic use , Serotonin Antagonists/therapeutic use , Transferrin/analogs & derivatives , Adult , Alcoholism/blood , Analysis of Variance , Cognitive Behavioral Therapy , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Middle Aged , Ondansetron/administration & dosage , Serotonin Antagonists/administration & dosage , Transferrin/metabolism
5.
Alcohol Alcohol ; 35(4): 319-23, 2000.
Article in English | MEDLINE | ID: mdl-10905994

ABSTRACT

In the human central nervous system, the gamma-aminobutyric acid (GABA) type A receptor complex undergoes changes with both acute and chronic exposure to sedative-hypnotic drugs. These changes contribute to both the acute effects of these drugs as well as the chronic effects of sedative-hypnotic dependence, withdrawal, and drug craving. Clinically these chronic effects are difficult to treat in patients dependent on ethanol or benzodiazepines. Valproate may return the GABA type A receptor function to a state more closely resembling its normal function. By this mechanism, it is possible to reduce the symptoms of sedative-hypnotic withdrawal and relapse.


Subject(s)
GABA Agents/pharmacology , GABA Agents/therapeutic use , Hypnotics and Sedatives/adverse effects , Substance Withdrawal Syndrome/drug therapy , Substance Withdrawal Syndrome/etiology , Valproic Acid/pharmacology , Valproic Acid/therapeutic use , Chronic Disease , Humans , Receptors, GABA-A/drug effects , Secondary Prevention
6.
Am J Addict ; 9(1): 17-27, 2000.
Article in English | MEDLINE | ID: mdl-10914290

ABSTRACT

Subtyping alcoholics may provide a more accurate guide as to the course and character of the disease. Classifications of different ages of onset of problem drinking have so far resulted in categorical inconsistencies. In the past, hospital-based alcoholics have over-represented those most severely ill, and comprehensive evaluations of psychopathology for discriminating between alcoholic subtypes have been infrequent. In a heterogeneous treatment-seeking, outpatient, alcoholic population, we tested the hypothesis that age of onset represents a continuum of disease, and that greater severity of psychopathology is associated with lower ages of onset. Using a standard questionnaire, 253 male and female treatment-seeking alcoholics were stratified according to specific ages of onset: a) < 20 years; b) 20-25 years, and c) > 25 years. These age of onset groups were compared on alcohol severity and craving, family history, childhood behavior, personality, hostility, overt aggression, mood, and social functioning. Symptom severity and age of onset were negatively correlated, and the 20-25-year onset group usually had intermediate scores. The < 20 year onset group was characterized by greater severity of alcohol-related problems, family history, childhood behavioral problems, craving, hostility, antisocial traits, mood disturbance, and poor social functioning. Alcoholics with an earlier age of onset have relatively greater psychopathology than those of later onset. While the preponderance of psychopathology among those in the < 20-year onset group could be conceptualized as a clinical "subtype," such a characterization would not define an entirely homogeneous category. Yet, this clinical characterization would be clinically important if specific age of onset levels were found to be differentially sensitive to pharmacological and/or psychological treatments.


Subject(s)
Alcoholism/classification , Adult , Affect , Age of Onset , Aged , Alcoholism/therapy , Female , Humans , Male , Middle Aged , Outpatients , Personality , Prognosis , Severity of Illness Index , Social Behavior , Surveys and Questionnaires
7.
J Clin Psychopharmacol ; 20(1): 61-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10653210

ABSTRACT

Two experiments examined the effects of methylphenidate in male and female patients enrolled in an outpatient treatment program for primary cocaine dependence. The first study was a component of a double-blind efficacy trial wherein 57 patients were first tested in a human laboratory for their initial responsiveness to medication. Patients were randomly assigned to receive either placebo or methylphenidate treatment and received their first dose in the human laboratory environment before continuing in outpatient treatment. Methylphenidate was given as a 20-mg sustained-release dose (twice daily) plus an additional 5-mg immediate-release dose combined with the morning dose. Methylphenidate increased heart rate and subjective ratings; however, the subjective effects were primarily of a "dysphoric" nature, and significant effects were limited to increases in anxiety, depression, and anger on the Profile of Mood States; shaky/jittery ratings on a visual analog scale; and dysphoria on the lysergic acid diethylamide (LSD) scale of the Addiction Research Center Inventory. Methylphenidate did not increase cocaine craving nor ratings suggesting abuse potential (i.e., Morphine-Benzedrine Group or drug-liking scores, etc.). None of the drug effects observed in the human laboratory was of clinical concern, and no subject was precluded from continuing in the outpatient study. After outpatient treatment completion, 12 patients were brought back into a second double-blind human laboratory study in which three doses (15, 30, and 60 mg) of immediate-release methylphenidate were administered in an ascending series preceded and followed by placebo. Methylphenidate produced dose-related increases in heart rate, subjective ratings of shaky/jittery, and LSD/dysphoria without significantly altering cocaine craving or stimulant euphoria ratings. These results suggest that stimulant substitution-type approaches to the treatment of cocaine dependence are not necessarily contraindicated because of cardiovascular toxicity or medication abuse potential. However, they also suggest that the subjective effects of methylphenidate may not be positive enough for an adequate replacement approach.


Subject(s)
Central Nervous System Stimulants/therapeutic use , Cocaine-Related Disorders/drug therapy , Methylphenidate/therapeutic use , Adult , Affect/drug effects , Analysis of Variance , Central Nervous System Stimulants/pharmacology , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Male , Methylphenidate/pharmacology , Middle Aged
8.
Exp Clin Psychopharmacol ; 7(4): 379-90, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10609973

ABSTRACT

Twenty-seven patients with generalized anxiety or panic disorder participated in a 6-week outpatient study. Participants received capsules containing either alprazolam or placebo and were free to choose between them for anxiety treatment. Measures of drug use included alprazolam preference, amount, and frequency of use. Alprazolam clearly was preferred over placebo; however, there were large between-subjects differences in the amount of medication used. A variety of demographic, drug history, personality, mood, and expectational variables were examined for correlation with medication use. Findings indicated that a substantial amount of variance in medication use could be explained by patients' intake characteristics. Findings also suggested that the tendency to consume capsules frequently may signal a greater risk factor for dependence than does drug preference in and of itself.


Subject(s)
Alprazolam/administration & dosage , Alprazolam/therapeutic use , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/drug therapy , Panic Disorder/drug therapy , Self Administration/psychology , Adult , Affect/drug effects , Anxiety Disorders/psychology , Double-Blind Method , Female , Humans , Individuality , Male , Middle Aged , Panic Disorder/psychology , Personality Tests , Psychiatric Status Rating Scales , Reinforcement, Psychology , Risk Factors
9.
Psychopharmacology (Berl) ; 144(3): 295-300, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10435398

ABSTRACT

RATIONALE: Dopamine (DA) pathways in the midbrain mediate d-methamphetamine's rewarding effects associated with its abuse liability. Isradipine, a dihydropyridine-class calcium channel antagonist, reduces the rewarding effects of psychostimulants such as cocaine and d-amphetamine, presumably by antagonizing these central DA pathways. This is the first experiment to test the hypothesis that the rewarding effects of d-methamphetamine, like other psychostimulants, can be reduced by isradipine. OBJECTIVE: We studied the effects of high dose isradipine (0.21 mg/kg orally), on the positive subjective effects associated with the abuse liability of low and high dose d-methamphetamine (0.21 mg/kg and 0.42 mg/kg orally, respectively). METHODS: Using a double-blind, double-dummy, placebo-controlled, Latin-Square, cross-over design, 18 healthy male and female volunteers received each of the following six treatments separated by a rest period of 2-7 days: a) placebo+placebo; b) low-dose d-methamphetamine+placebo); c) high-dose d-methamphetamine+placebo; d) high dose isradipine+placebo); e) low-dose d-methamphetamine+high dose isradipine, and f) high-dose d-methamphetamine+high dose isradipine. RESULTS: d-Methamphetamine produced orderly increases in positive subjective measures of both stimulation and mood. Pre-treatment with isradipine significantly reduced some of these positive subjective effects and craving for d-methamphetamine. CONCLUSION: Isradipine as an anti-reward or craving reducing medication is a promising therapeutic agent for the treatment of d-methamphetamine dependence.


Subject(s)
Adrenergic Agents/pharmacology , Calcium Channel Blockers/pharmacology , Isradipine/pharmacology , Methamphetamine/pharmacology , Adult , Affect/drug effects , Calcium Channel Blockers/therapeutic use , Cross-Over Studies , Dihydropyridines/pharmacology , Dihydropyridines/therapeutic use , Double-Blind Method , Drug Antagonism , Female , Humans , Isradipine/therapeutic use , Male , Methamphetamine/antagonists & inhibitors , Middle Aged , Reinforcement, Psychology , Reward , Substance-Related Disorders/drug therapy
10.
J Clin Psychopharmacol ; 17(6): 485-8, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9408812

ABSTRACT

Agonists, or "replacement medications," are useful adjuncts in treatment of opiate and nicotine dependence. They have not been systematically examined in cocaine dependence. Results of early open trials with methylphenidate for treatment of cocaine dependence were equivocal. Twenty-four cocaine-dependent subjects were enrolled in an 11-week double-blind, placebo-controlled study of methylphenidate. Assignment was random. Intake included a 2-day human laboratory procedure in which subjects received initial doses of methylphenidate or placebo. Subjects attended the clinic Monday through Friday and received oral doses of methylphenidate (5 mg plus 20-mg sustained release) or placebo at 8:00 a.m., with afternoon and weekend take-home doses (20 mg sustained-release or placebo) provided in Medication Events Monitoring System bottles to monitor compliance. Clinic visits included therapy sessions, electrocardiograms, self-report measures, and twice-weekly urine screens. The two groups were equivalent in terms of retention (methylphenidate 48% and placebo 42%) and had similar cocaine use outcomes (40% benzoylecgonine-positive urine screens). There were no significant adverse effects. The doses were sufficient to permit detection of psychoactive effects ("stimulant," "more energy") and side effects ("jitteriness," "eating less") without increased "craving." Additional medications with different effects profiles are being studied to further evaluate the replacement model in cocaine dependence.


Subject(s)
Central Nervous System Stimulants/therapeutic use , Cocaine-Related Disorders/drug therapy , Methylphenidate/therapeutic use , Adult , Female , Humans , Male
11.
Exp Clin Psychopharmacol ; 5(3): 203-15, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9260068

ABSTRACT

The behavioral and subjective effects of acute oral doses of placebo, ethanol (0.5, 1.0, and 2.0 g/kg), and pentobarbital (150, 300, 600, and 750 mg/70 kg) were compared in 8 male volunteers with histories of sedative drug abuse using a double-blind, double-dummy, cross-over design. Ethanol and pentobarbital produced similar dose-related decrements in psychomotor and cognitive performance and exhibited a similar profile of effects on staff- and participant-rated measures. There was some evidence indicating that, at the highest dose, pentobarbital was perceived by participants as being more sedating than ethanol and that pentobarbital has a greater abuse liability than ethanol. In conjunction with the results of previous human laboratory studies comparing the effects of different types of sedative-hypnotic drugs, these results support a mostly barbiturate-like rather than benzodiazepine-like profile of effects for ethanol.


Subject(s)
Behavior/drug effects , Central Nervous System Depressants/pharmacology , Ethanol/pharmacology , Hypnotics and Sedatives/pharmacology , Pentobarbital/pharmacology , Substance-Related Disorders/psychology , Adult , Affect/drug effects , Breath Tests , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Male , Memory, Short-Term/drug effects , Mental Recall/drug effects , Psychomotor Performance/drug effects
12.
Drug Alcohol Depend ; 45(3): 143-55, 1997 May 02.
Article in English | MEDLINE | ID: mdl-9179516

ABSTRACT

The reinforcing effects of alprazolam were investigated in 14 patients who had generalized anxiety or panic disorder, but were not current users/abusers of other psychoactive substances. Using a double-blind outpatient choice procedure, color-coded alprazolam (0.5 mg) and placebo capsules were provided to patients for use 'as needed' in the treatment of anxiety symptoms. Comparisons of alprazolam and placebo during a 2 week sampling period in which placebo and alprazolam were available sequentially revealed no significant differences on measures of medication usage or anxiety levels, although alprazolam did increase subjective ratings of drug effects side effects. During a 4 week choice period, alprazolam was strongly preferred over placebo in 11 out of 14 patients indicating that alprazolam functioned as a reinforcer. Medication usage ranged from zero to 4.0 mg alprazolam in a day. Variations in daily medication-use were positively correlated with anxiety level fluctuations for a majority of patients. For a majority of patients, the results indicate that alprazolam functioned as a reinforcer without accompanying signs of abuse or addiction.


Subject(s)
Alprazolam/therapeutic use , Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/drug therapy , Behavior, Addictive , Panic Disorder/drug therapy , Reinforcement, Psychology , Adult , Analysis of Variance , Choice Behavior , Circadian Rhythm , Double-Blind Method , Female , Follow-Up Studies , Humans , Individuality , Longitudinal Studies , Male , Middle Aged , Placebos , Self Administration/psychology , Treatment Outcome
13.
Behav Pharmacol ; 8(1): 91-100, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9833005

ABSTRACT

The effects of work requirement on human ethanol self-administration were systematically examined. Healthy volunteers with a history of moderate alcohol consumption (12 to 16 drinks per week) were recruited as subjects. Four subjects self-administered 4, 8 or 16% w/v ethanol solution contingent upon completion of a fixed-ratio (FR) response requirement. The ratio requirements were FR 32, FR 64 and FR 128 responses. Ethanol consumption at lower doses decreased with increases in FR. Ethanol consumption at the high dose was greatest across all ratio requirements and was unchanged by increases in the ratio requirement, indicating greater relative reinforcing effects of the high dose of ethanol. Ethanol consumption was sensitive to unit price with 53-82% of the variance explained by the unit price analysis.


Subject(s)
Alcohol Drinking/psychology , Central Nervous System Depressants/pharmacology , Ethanol/pharmacology , Adult , Alcohol Drinking/blood , Central Nervous System Depressants/administration & dosage , Central Nervous System Depressants/blood , Dose-Response Relationship, Drug , Ethanol/administration & dosage , Ethanol/blood , Humans , Male , Psychomotor Performance/drug effects , Self Administration/psychology
14.
Psychopharmacology (Berl) ; 118(4): 377-84, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7568623

ABSTRACT

Twenty-five managers who reported an average daily caffeine consumption of 575 mg participated in two complex simulations. A double-blind cross-over design was employed to assess the effects of normal caffeine consumption versus caffeine deprivation upon seven validated measures of managerial effectiveness. Data from a Caffeine Withdrawal Questionnaire indicated discomfort upon deprivation. Systolic blood pressure increased during "normal" caffeine consumption levels but fell quickly and remained lower during deprivation. Several measures of managerial performance indicated decreased effectiveness upon caffeine deprivation. In contrast to prior research from simpler task settings, cognitive effectiveness (during complex task performance) was diminished. However, a measure of strategic performance which requires a relatively high level of cognitive effort showed no impact of caffeine deprivation.


Subject(s)
Caffeine/adverse effects , Caffeine/pharmacology , Mental Processes/drug effects , Substance Withdrawal Syndrome/physiopathology , Adult , Blood Pressure/drug effects , Cross-Over Studies , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Surveys and Questionnaires , Task Performance and Analysis
15.
Pharmacol Biochem Behav ; 50(2): 171-9, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7740055

ABSTRACT

Six male subjects with histories of sedative abuse were allowed to orally self-administer a maximum of 18 color-coded triazolam and placebo capsules during daily 3-h sessions. The schedule of reinforcement was a signaled fixed-interval 10-min schedule in which triazolam and placebo were concurrently available as mutually exclusive choices. Triazolam was shown to be a reinforcer in four of the six subjects. The two subjects who did not self-administer triazolam in preference to placebo also had lesser histories of drug dependence. Self-administration of triazolam (0.125 or 0.25 mg per capsule) was generally stable over 7-10 days. Manipulations of triazolam dose (0.0312-0.25 mg) per capsule in two subjects showed that the number of capsules self-administered was inversely related to capsule dose. Subject ratings of drug liking obtained from experimenter-administered doses of triazolam were correlated with self-administration behavior occurring 1-7 days later. Of the subject ratings, next day ratings obtained on the day after dosing resulted in significant correlations whereas same day ratings obtained while subjects were under the influence of triazolam did not. These results have important implications for abuse liability prediction and suggest that next day ratings have greater predictive validity than measures collected while subjects are under the influence of benzodiazepines.


Subject(s)
Hypnotics and Sedatives , Substance-Related Disorders/psychology , Triazolam/pharmacology , Adult , Anxiety/chemically induced , Anxiety/psychology , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Male , Reinforcement Schedule , Reinforcement, Psychology , Self Administration , Yohimbine/pharmacology
16.
J Pharmacol Exp Ther ; 271(1): 200-11, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7965716

ABSTRACT

Oral benzodiazepine self-administration was examined in four adult male rhesus monkeys with histories of ethanol- and pentobarbital-reinforced behavior. Drug solutions and vehicle were concurrently available for 3-hr each day under fixed-ratio (FR) reinforcement schedules. Initially, the monkeys rejected a midazolam solution (0.1 mg/ml) after direct substitution of the drug for an 8% ethanol solution. However, midazolam self-administration was subsequently established by using a fading procedure in which increasing amounts of drug (0.0125-0.2 mg/ml) were gradually added to an 8% ethanol solution, followed by gradual reduction of the ethanol concentration to zero. Midazolam was an effective reinforcer for three of four monkeys tested, i.e., responding that was maintained by the drug solution exceeded that maintained by the drug vehicle. The fourth monkey also self-administered midazolam but drug-maintained responding was not consistently greater than vehicle-maintained responding. The responding maintained by the drug was an inverted-U-shaped or bitonic function of midazolam concentration. The midazolam intake (in milligrams per kilogram) increased as a function of increases in the drug concentration. At the higher concentrations, marked sedative intoxication was observed. There was an inverse relationship between FR size (varied from FR 8 to FR 32) and the amount of drug self-administered. The three monkeys in which midazolam functioned as a reinforcer were then tested with diazepam (0.2 mg/ml), which maintained drug self-administration behavior on direct substitution for 0.2-mg/ml midazolam. Diazepam-maintained responding usually exceeded water responding as the diazepam concentration was increased to 0.8 mg/ml. These data demonstrate robust reinforcing effects of both "short-" and "long-acting" benzodiazepines delivered by the oral route.


Subject(s)
Diazepam/pharmacology , Midazolam/pharmacology , Reinforcement, Psychology , Administration, Oral , Animals , Dose-Response Relationship, Drug , Ethanol/pharmacology , Hydrochloric Acid/pharmacology , Macaca mulatta , Male
17.
J Exp Anal Behav ; 62(1): 73-87, 1994 Jul.
Article in English | MEDLINE | ID: mdl-8064214

ABSTRACT

In three experiments, 8 human subjects participated in a study of the effects of smoked marijuana on progressive-interval schedule performance. A two-component chained progressive-interval fixed-interval schedule of point delivery was used. In the progressive-interval component, the interval length began at 20 s and increased either geometrically or arithmetically (by either 20 s, 40 s, 80 s, 100 s, or 160 s) on each subsequent interval. After this interval elapsed, a single button press produced the fixed-interval component, with a total of five reinforcers of varying magnitude ($0.05, $0.20, or $0.40) available on a fixed-interval 20-s schedule. After the five reinforcer deliveries, the schedule returned to the initial progressive-interval component. Several relationships were found among rates of responding, postreinforcement pauses and drug administration in the progressive-interval component: (a) Postreinforcement pauses increased as the temporal requirements of the progressive-interval schedule increased; (b) rates of responding during successive progressive-interval components rapidly decreased to low rates of responding after the first few progressions; (c) postreinforcement pauses decreased systematically as dose of smoked marijuana increased; and (d) rates of responding increased after smoking active marijuana but not after smoking placebo cigarettes. Results are discussed in the context of behavioral control and relevance to other studies that have investigated the effects of smoked marijuana on schedule performance.


Subject(s)
Cannabis , Smoking , Adult , Dose-Response Relationship, Drug , Heart Rate , Humans , Infant, Newborn , Male , Placebos , Reinforcement Schedule , Reinforcement, Psychology , Time Factors
18.
J Pharmacol Exp Ther ; 265(3): 1163-74, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8510001

ABSTRACT

The effects of i.v. administered flumazenil (3.0 mg) were studied in healthy male subjects who received pretreatment with p.o. placebo or lorazepam. The duration of placebo or lorazepam (3.0 mg single p.o. daily dose) pretreatment before a flumazenil or placebo injection was 1, 3, 7 or 14 days in four sequential groups of subjects. Initial administration of lorazepam produced a classic sedative profile of effects on various psychomotor/behavioral performance, observer-rated and subject-rated measures. Tolerance to repeated daily administration of lorazepam was suggested by a progressive diminution of performance disrupting effects. In subjects pretreated with placebo, flumazenil increased subject-ratings of dizziness over preinjection ratings. Flumazenil produced an immediate reversal of lorazepam effects in subjects who were not tolerant to lorazepam (1- and 3-day pretreatment groups). Flumazenil did not precipitate withdrawal symptoms in subjects who received a single administration of lorazepam. Precipitated withdrawal symptoms were evident after 3 and 7 days of lorazepam pretreatment, and there was a tendency toward precipitated withdrawal symptoms (that included one panic attack) after 14 days of lorazepam pretreatment. Precipitated withdrawal was characterized by an elevation in subject-rated symptoms including dizziness, tenseness, tachycardia, perceptual disturbance and sweating. Symptoms were maximal immediately after injection, usually mild in severity and usually resolved within 1 hr. There was no evidence of precipitated withdrawal on psychomotor/behavioral performance or observer ratings. The present study provides the strongest human experimental evidence to date that flumazenil can precipitate withdrawal symptoms after a history of repeated benzodiazepine exposure.


Subject(s)
Flumazenil/pharmacology , Lorazepam/adverse effects , Substance Withdrawal Syndrome , Adolescent , Adult , Drug Interactions , Flumazenil/administration & dosage , Hemodynamics/drug effects , Humans , Injections, Intravenous , Lorazepam/administration & dosage , Lorazepam/blood , Male , Middle Aged , Reference Values , Respiration/drug effects
19.
Drug Alcohol Depend ; 32(3): 219-29, 1993 May.
Article in English | MEDLINE | ID: mdl-8348874

ABSTRACT

The effects of placebo, triazolam (2.0, 4.0 and 8.0 micrograms/kg) and ethanol (0.25, 0.5, 1.0 g/kg) on perceptual-motor performance were examined using a visual pattern matching-to-sample procedure in which pattern size and comparison stimulus discriminability were systematically varied. Baseline response rates and accuracy increased as the discriminability of the comparison stimuli increased. At the highest dose, both drugs decreased response accuracy. This disruption of accuracy was attenuated by increasing the discriminability of non-matching stimuli. Triazolam produced dose-related decreases in response rate while ethanol produced only slight decreases at the highest baseline rates of responding. Thus, triazolam produced response rate slowing at relatively lower doses than ethanol.


Subject(s)
Alcohol Drinking/psychology , Attention/drug effects , Discrimination Learning/drug effects , Pattern Recognition, Visual/drug effects , Psychomotor Performance/drug effects , Size Perception/drug effects , Triazolam/pharmacology , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Male , Mental Recall/drug effects , Reaction Time/drug effects
20.
J Clin Psychopharmacol ; 13(1): 3-15, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8486815

ABSTRACT

Eight normal, healthy, male volunteers each received four triazolam doses (0, 2, 4, and 8 micrograms/kg) and four ethanol doses (0, 0.25, 0.5 and 1.0 g/kg) in a double-blind, double-dummy experiment in which within-subject dose sequence was determined by a balanced Latin square design. Triazolam and ethanol produced dose-related and time-related effects on subject ratings of mood and perceived drug effects and objective measures of memory and psychomotor performance. Dose-response curves for the two drugs were not parallel, and therefore, comparisons of the two drugs were based upon comparisons of the high dose of each drug. Although the two high-dose conditions generally were not different from one another, there were differences in their relative effect sizes, which were important. The high dose of each drug produced comparable degrees of impairment on two different psychomotor tasks. Triazolam, but not ethanol, produced significant impairment on two different memory tasks. The relative effects of each drug on subject ratings of mood and perceived drug effects varied across different subject-rated measures. Only ethanol significantly increased subject ratings of alcohol strength and feeling drunk. In comparison to ethanol, triazolam tended to produce less-pronounced subject ratings of drug effect magnitude, drug liking, and estimated performance impairment. However, less-pronounced subjective effects of triazolam were not universally observed on all subject ratings. Triazolam produced greater effects on several sedative symptoms and produced comparable effects on several mood factor scales.


Subject(s)
Alcohol Drinking/psychology , Awareness/drug effects , Ethanol/pharmacology , Mental Recall/drug effects , Psychomotor Performance/drug effects , Triazolam/pharmacology , Adult , Breath Tests , Dose-Response Relationship, Drug , Double-Blind Method , Ethanol/pharmacokinetics , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...